Gain Therapeutics (GANX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.26, -5.26% vs the prior close of $1.33.
- Volume 464.37K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GANX slides 5.3% to $1.26, a 52-week low. Closed at $1.26, -5.26% vs the prior close of $1.33. Day range $1.24–$1.38, opened at $1.32.
GANX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — GANX slides 5.3% to $1.26, a 52-week low
- Closed at $1.26, -5.26% vs the prior close of $1.33. Day range $1.24–$1.38, opened at $1.32.
- Volume was 464.37K shares, 1.0x its 50-day average of 470.51K.
- Price is -29.4% vs its 50-day average ($1.78) and -34.6% vs its 200-day average ($1.93).
- 52-week range $1.24–$4.34; today's close sits at 1% of that range, 71.0% below the 52-week high.
Oct 15, 2026 — GANX rises 0.8% to $1.33
- Closed at $1.33, +0.76% vs the prior close of $1.32. Day range $1.31–$1.41, opened at $1.32.
- Volume was 501.30K shares, 1.1x its 50-day average of 466.44K.
- Price is -25.9% vs its 50-day average ($1.80) and -31.3% vs its 200-day average ($1.94).
- 52-week range $1.29–$4.34; today's close sits at 1% of that range, 69.4% below the 52-week high.
Oct 14, 2026 — GANX slides 6.4% to $1.32, a 52-week low on 1.9x normal volume
- Closed at $1.32, -6.38% vs the prior close of $1.41. Day range $1.29–$1.42, opened at $1.37.
- Volume was 849.30K shares, 1.9x its 50-day average of 455.10K — unusually heavy trading.
- Price is -26.9% vs its 50-day average ($1.80) and -32.2% vs its 200-day average ($1.95).
- 52-week range $1.29–$4.34; today's close sits at 1% of that range, 69.6% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GANX slides 10.2% to $1.41, a 52-week low
- Closed at $1.41, -10.19% vs the prior close of $1.57. Day range $1.40–$1.58, opened at $1.58.
- Volume was 790.90K shares, 1.8x its 50-day average of 447.10K.
- Price is -22.3% vs its 50-day average ($1.81) and -27.9% vs its 200-day average ($1.96).
- 52-week range $1.40–$4.34; today's close sits at 0% of that range, 67.5% below the 52-week high.
Oct 12, 2026 — GANX slides 4.3% to $1.57, a 52-week low
- Closed at $1.57, -4.27% vs the prior close of $1.64. Day range $1.57–$1.65, opened at $1.65.
- Volume was 319.60K shares, 0.7x its 50-day average of 445.32K.
- Price is -13.8% vs its 50-day average ($1.82) and -20.1% vs its 200-day average ($1.96).
- 52-week range $1.53–$4.34; today's close sits at 1% of that range, 63.8% below the 52-week high.
Oct 9, 2026 — GANX rises 1.5% to $1.64
- Closed at $1.64, +1.55% vs the prior close of $1.62. Day range $1.61–$1.66, opened at $1.61.
- Volume was 328.60K shares, 0.7x its 50-day average of 452.67K.
- Price is -10.0% vs its 50-day average ($1.82) and -16.8% vs its 200-day average ($1.97).
- 52-week range $1.53–$4.34; today's close sits at 4% of that range, 62.2% below the 52-week high.
Oct 8, 2026 — GANX slides 3.3% to $1.62, a 3-month low, 6 down days in a row
- Closed at $1.62, -3.29% vs the prior close of $1.67. Day range $1.61–$1.67, opened at $1.66.
- Volume was 361.50K shares, 0.8x its 50-day average of 456.29K.
- Price is -11.5% vs its 50-day average ($1.82) and -18.4% vs its 200-day average ($1.98).
- 52-week range $1.53–$4.34; today's close sits at 3% of that range, 62.8% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — GANX ends flat (+0.0%) to $1.67, 5 down days in a row
- Closed at $1.67, +0.00% vs the prior close of $1.67. Day range $1.64–$1.69, opened at $1.66.
- Volume was 372.40K shares, 0.8x its 50-day average of 455.35K.
- Price is -8.6% vs its 50-day average ($1.83) and -15.9% vs its 200-day average ($1.99).
- 52-week range $1.53–$4.34; today's close sits at 5% of that range, 61.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — GANX dips 1.2% to $1.67, a 1-month low, 4 down days in a row
- Closed at $1.67, -1.18% vs the prior close of $1.69. Day range $1.65–$1.75, opened at $1.70.
- Volume was 644.90K shares, 1.4x its 50-day average of 450.37K.
- Price is -8.6% vs its 50-day average ($1.83) and -16.0% vs its 200-day average ($1.99).
- 52-week range $1.53–$4.34; today's close sits at 5% of that range, 61.5% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — GANX dips 1.2% to $1.69, 3 down days in a row
- Closed at $1.69, -1.17% vs the prior close of $1.71. Day range $1.69–$1.77, opened at $1.75.
- Volume was 346.60K shares, 0.8x its 50-day average of 452.88K.
- Price is -7.7% vs its 50-day average ($1.83) and -15.5% vs its 200-day average ($2.00).
- 52-week range $1.53–$4.34; today's close sits at 6% of that range, 61.1% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — GANX dips 0.6% to $1.71
- Closed at $1.71, -0.58% vs the prior close of $1.72. Day range $1.70–$1.78, opened at $1.75.
- Volume was 383.90K shares, 0.8x its 50-day average of 453.83K.
- Price is -6.7% vs its 50-day average ($1.83) and -15.0% vs its 200-day average ($2.01).
- 52-week range $1.53–$4.34; today's close sits at 6% of that range, 60.6% below the 52-week high.
GANX latest news & SEC filings
Every SEC filing by or about GANX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$4.68M (prior year -$5.81M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.19) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade GANX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 26, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.16% (largest 10.2%). That is a volatile stock.
- Liquidity: about 529.54K shares (≈$667.22K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.26 vs a range of $1.24–$4.34 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 1, 2026; 8-K Sep 28, 2026; 10-Q Aug 11, 2026.
- Share count: 43.64M shares outstanding (Jul 31, 2026), +21.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GANX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.32 | 1.38 | 1.24 | 1.26 | 464.37K |
| Oct 15, 2026 | 1.32 | 1.41 | 1.31 | 1.33 | 501.30K |
| Oct 14, 2026 | 1.37 | 1.42 | 1.29 | 1.32 | 849.30K |
| Oct 13, 2026 | 1.58 | 1.58 | 1.40 | 1.41 | 790.90K |
| Oct 12, 2026 | 1.65 | 1.65 | 1.57 | 1.57 | 319.60K |
| Oct 9, 2026 | 1.61 | 1.66 | 1.61 | 1.64 | 328.60K |
| Oct 8, 2026 | 1.66 | 1.67 | 1.61 | 1.62 | 361.50K |
| Oct 7, 2026 | 1.66 | 1.69 | 1.64 | 1.67 | 372.40K |
| Oct 6, 2026 | 1.70 | 1.75 | 1.65 | 1.67 | 644.90K |
| Oct 5, 2026 | 1.75 | 1.77 | 1.69 | 1.69 | 346.60K |
| Oct 2, 2026 | 1.75 | 1.78 | 1.70 | 1.71 | 383.90K |
| Oct 1, 2026 | 1.73 | 1.77 | 1.67 | 1.72 | 494.10K |
| Sep 30, 2026 | 1.70 | 1.84 | 1.69 | 1.73 | 787.00K |
| Sep 29, 2026 | 1.75 | 1.76 | 1.60 | 1.68 | 1.29M |
| Sep 28, 2026 | 1.75 | 1.82 | 1.72 | 1.77 | 547.10K |
| Sep 25, 2026 | 1.85 | 1.88 | 1.77 | 1.78 | 382.90K |
| Sep 24, 2026 | 1.84 | 1.86 | 1.79 | 1.84 | 405.70K |
| Sep 23, 2026 | 1.91 | 1.97 | 1.83 | 1.84 | 292.90K |
| Sep 22, 2026 | 1.85 | 1.96 | 1.83 | 1.95 | 692.00K |
| Sep 21, 2026 | 1.80 | 1.85 | 1.78 | 1.84 | 335.80K |
About Gain Therapeutics
Gain Therapeutics (GANX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BETHESDA, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1819411.
GANX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dov A Md Goldstein | Director | Jul 17, 2026 |
| Hans Peter Hasler | Director | Jul 17, 2026 |
| Khalid Islam | Director | Jul 17, 2026 |
| Gene Mack | CEO, President | Mar 26, 2026 |
| Gwen A Melincoff | Director | Jul 17, 2026 |
| Claude Nicaise | Director | Jul 17, 2026 |
| Jeffrey Scott Riley | Director | Jul 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gianluca Fuggetta | See Remark | Mar 26, 2026 |
| Gene Mack | CEO, President | Mar 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
GANX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-20.16M | -0.61 | $-18.47M |
| Dec 31, 2024 | — | $-20.41M | -0.89 | $-18.87M |
| Dec 31, 2023 | $55.18K | $-22.27M | -1.71 | $-18.87M |
| Dec 31, 2022 | $132.64K | $-17.59M | -1.48 | $-14.69M |
| Dec 31, 2021 | $133.93K | $-13.89M | -1.37 | $-12.37M |
Latest balance sheet: total assets $15.42M, total liabilities $4.13M, cash $13.08M (as of Jun 30, 2026).
GANX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $2.06 |
| May 11, 2026 | 8-K Item 2.02 (results) | $1.82 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $1.89 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $2.95 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.53 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.86 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $2.07 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $1.75 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on GANX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.